Advancing Small Molecules, Peptides & Antibodies to Drug Novel GPCRs in Multiple Indications with Improved Selectivity, Safety & Efficacy
The GPCR field is accelerating fast. Breakthroughs in cryo‑EM, AI‑enabled structure prediction, and high‑resolution screening are opening up receptor families once considered “undruggable,” while biopharma investment is surging as new GPCR programmes advance in oncology, immunology, neurology, and rare disease. With fresh clinical readouts, renewed big‑pharma pipelines, and next‑generation tools revealing previously hidden receptor dynamics, GPCR drug discovery is entering its most exciting phase in over a decade.
Returning as the only industry‑led meeting dedicated exclusively to GPCR drug discovery, the 5th GPCR-Targeted Drug Discovery Summit brings together leading innovators from across biopharma, including AbbVie, Abalone Bio, Eli Lilly, Confo, Kainova, Superluminal and Tectonic, to share cutting‑edge insights on emerging targets, tools, and therapeutic strategies.
Join GPCR‑focused experts shaping the next wave of discovery and development, build new collaborations, and help advance the next generation of GPCR‑targeted therapeutics from concept to clinic.
The scope of the conference covers quite the range of therapeutic indications allowing me to broadly understand current GPCR discovery activities, as well as those drug targets of current therapeutic interest.
Glenn Short, Chief Scientific Officer, Atai Life Sciences
Participating in this meeting is a valuable opportunity to both learn from and contribute to state-of-the-art discussions on GPCR biology and drug discovery. I see this meeting as a forum for open scientific exchange, new collaborations, and critical dialogue on emerging technologies and ideas that will shape the next generation of GPCR-targeted therapeutics.
William Barnes, Executive Director – Head of GPCR Biology, Iambic Therapeutics
This meeting will help pharmacology, medicinal chemistry, and investor leaders with deep interests in GPCR targets to get a “lay of the land” of numerous innovative approaches to measuring, modeling, and modulating GPCR structure and function. How can these insights be leveraged for successful drug discovery?
Chris Dockendorff, Chief Executive Officer & Chief Scientific Officer, Function Therapeutics
Explore The Full Event Guide
- 80+ Attendees
- 25+ World-Class Speakers
- 21+ Data-Driven Presentations
- 7+ Hours of Networking
- 1 AI & ML Focus Day
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug discovery and make critical connections during our dedicated networking sessions
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.